2nd Quarter - Report — MAYO CLINIC for MAYO CLINIC (2019)

Firm

MAYO CLINIC

Client

MAYO CLINIC

Income

—

Expenses

$250,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Opioid Epidemic (H.R. 6); clinical pain management

Lobbyist	Covered position, as disclosed
JENNIFER MALLARD	—

Contacted: Natl Institutes of Health (NIH); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6 (116th)

Taxation/Internal Revenue Code TAX

Tax Reform; Tax Cuts and Jobs Act (H.R. 1)

Lobbyist	Covered position, as disclosed
JENNIFER MALLARD	—

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1 (116th)

Medicare/Medicaid MMM

Medicare physician payments; Medicare hospital payments; Medicare clinical lab payments; Quality; Telemedicine; Drug Pricing

Lobbyist	Covered position, as disclosed
JENNIFER MALLARD	Director, Federal Government Relations

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS)

Medical/Disease Research/Clinical Labs MED

PAMA (Lab Payments); Medical Research Funding; Regulatory Relief; Laboratory Diagnostic Tests

Lobbyist	Covered position, as disclosed
JENNIFER MALLARD	Director, Federal Government Relations

Contacted: Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Science/Technology SCI

Telemedicine technology; New Diagnostic tests, Precision Medicine; NextGen Sequencing

Lobbyist	Covered position, as disclosed
JENNIFER MALLARD	—

Contacted: Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Natl Institutes of Health (NIH)

Health Issues HCR

Telemedicine; Laboratory Medicine payment and oversight

Lobbyist	Covered position, as disclosed
JENNIFER MALLARD	Director, Federal Government Relations

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH)

Pharmacy PHA

Drug Shortage; Drug Pricing; Opioid Epidemic (H.R. 6); 340B Program

Lobbyist	Covered position, as disclosed
JENNIFER MALLARD	—

Contacted: Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE

Bills named: H.R. 6 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.